The Dopamine D1 Receptor: Biochemical and Behavioral Aspects

  • Peter H. Andersen
  • Erik B. Nielsen
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 204)


Research on the role of dopamine (DA) in the control of behavior was initiated with the studies by Randrup and colleagues in the early 60’es (e.g., Randrup et al., 1965). However, the direct study of DA receptors began with the discovery in 1972 of DA sensitive adenylate cyclase in rat striatum (Kebabian et al., 1972). In 1975, tritiated haloperidol was introduced as a compound for direct labelling of DA receptors (Creese et al., 1975; Burt et al., 1975; Seeman et al., 1975). Comparing the pharmacological characteristics of DA stimulated adenylate cyclase and 3H-haloperidol binding, it was readily apparent that 3H-haloperidol does not label the same site as the one through which DA exerts its effects on adenylate cyclase. These discrepancies between binding data and functional data, resulted a few years later in the postulated existence by Kebabian and Calne (1979) of two types of DA receptors designated D1 and D2. The D1 receptor was defined by means of its coupling in a stimulatory fashion to the adenylate cyclase while the D2 receptor was associated in an inhibitory fashion to or uncoupled from the same effector system.


Dopamine Receptor Adenylate Cyclase Stimulate Adenylate Cyclase Dopamine Receptor Binding Sensitive Adenylate Cyclase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Andersen P.H., Groenvald F.C., and Jansen J. A., 1985, A comparison between dopamine-stimulated adenylate cyclase and 3H-SCH 23390 binding in rat striatum, Life Sci., 37:1971–1983.PubMedCrossRefGoogle Scholar
  2. Andersen, P.H. and Groenvald F.C., Specific binding of 3H-SCH 23390 to dopamine D1 receptors in vivo. Life Sci., in press.Google Scholar
  3. Andersen P.H., Nielsen, E.B., Groenvald F.C. and Braestrup C., Some atypical neuroleptics inhibit 3H-SCH 23390 binding in vivo, Eur. J. Pharmacol., 120:143–144.Google Scholar
  4. Apud J.A., Masotto C., Ongini E. and Racagni G., 1985, Interaction of SCH 23390, a D1 selective antagonist with the anterior pituitary D2 receptors and prolactin secretion in the rat, Eur. J. Pharmacol., 112:187–193.PubMedCrossRefGoogle Scholar
  5. Arnt J., 1984, Differential inhibition by dopamine D1 and D2 antagonists of circling behaviour induced by dopamine agonists in rats with unilateral 6-OHDA lesions, Eur. J. Pharmacol., 102:349–354.PubMedCrossRefGoogle Scholar
  6. Arnt J., 1985, Hyperactivity induced by stimulations of separate D1 and D2 receptors in rats with bilateral 6-OHDA lesions, Life Sci., 37:717–723.PubMedCrossRefGoogle Scholar
  7. Braestrup C., Schmiechen R., Nielsen M. and Petersen E.N., 1982, Benzodiazepine receptor ligands, receptor occupancy, pharmacological effect and GABA receptor coupling. In: The Pharmacology of Benzodiazepine, Usdin E., Skolnick P., Tallman J.F., Greenblatt D. and Paul S.M. (eds) pp 71–85, MacMillan Press, London, UK.Google Scholar
  8. Billard W., Ruperto G., Grosby L.C., Iorio L.C, and Barnett A., 1984, Characterization of the binding of 3H-SCH 23390, a selective D1 receptor antagonist ligand, in rat striatum, Life Sci., 35:1885–1893.PubMedCrossRefGoogle Scholar
  9. Brown J.H. and Brown S.L., 1984, Agonists differentiate muscarinic receptors that inhibit cyclic AMP formation from those that stimulate phosphoionsitide metabolism, J. Biol. Chem., 259:3777–3781.PubMedGoogle Scholar
  10. Burt D.R., Enna S.J., Creese I. and Snyder S.M., 1975, Dopamine receptor binding in the corpus striatum of mammalian brain, Proc. Natl. Acad. Sci., USA, 72:4655–4659.PubMedCrossRefGoogle Scholar
  11. Chang R.S.L. and Snyder S.H., 1978, Benzodiazepine receptors: Labeling in intact animals with 3H-flunitrazepam, Eur. J. Pharmacol., 48:213–218.PubMedCrossRefGoogle Scholar
  12. Christensen A.V., Arnt J., Hyttel J., Larsen J.-J. and Svendsen O., 1984, Pharmacological effects of a specific dopamine D1 antagonist SCH 23290 in comparison with neuroleptics, Life Sci., 34:1529–1540.PubMedCrossRefGoogle Scholar
  13. Clement-Cormier Y.C., Kebabian J.W., Petzold G.L., and Greengard P., 1974, Dopamine-sensitive adenylate cyclase in Mammalian brain: A possible site of action of antipsychotic drugs, Proc. Natl. Acad. Sci., USA, 71: 1113–1117.PubMedCrossRefGoogle Scholar
  14. Creese I., Burt D.R. and Snyder S.H., 1975, Dopamine receptor binding: differentiation of agonist and antagonist states with 3H-dopamine and 3H-haloperidol, Life Sci., 17:993–1002.CrossRefGoogle Scholar
  15. Creese I., Sibley D.R. and Leff S.E., 1984, Agonist interactions with dopamine receptors: focus on radiolig and-binding studies, Fed. Proc., 43:2779–2784.PubMedGoogle Scholar
  16. Cross A.J. and Waddington J.L., 1981, Kainic acid lesions dissociate 3H-spiperone and 3H-flupentixol binding sites in rat striatum, Eur. J. Pharmacol., 71:327–332.PubMedCrossRefGoogle Scholar
  17. Cunningham K.A., Callahan P.M. and Appel J.B., 1985, Dopamine D1 receptor mediation of discriminative stimulus properties of SKF 38393, Eur. J. Pharmacol., 119:121–125.PubMedCrossRefGoogle Scholar
  18. Fleminger S., Jenner P., Marsden C.D. and Rupniak N.M., 1982, Dopamine receptor supersensitivity produced by repeated neuroleptic administration correlates with D2 receptors. Br. J. Pharmacol., 77:456P.Google Scholar
  19. Fleminger S., Hall M.D., Jenner P., Kilpatrick G., Mann S., Marsden C.D. and Rupniak N.M., 1984, Differential effects of administration of haloperidol, sulpiride or clozapine for 12 months on rat striatal function, Br. J. Pharmacol., 82:288P.Google Scholar
  20. Haga K., Haga T., Ichiyama A., Katada T., Kurose H., and Ui M., 1985, Functional reconstitution of purified muscarinic receptors and inhibitory quanine nucleotide regulatory protein, Nature, 316:731–733.PubMedCrossRefGoogle Scholar
  21. Hirata F., Strittmatter W.J. and Axelrod J., 1979, Beta-adrenergic receptor agonists increase phospholipid methylation, membrane fluidity and beta-adrenergic receptor adenylate cyclase coupling, Proc. Natl. Acad. Sci., USA 76:368–372.PubMedCrossRefGoogle Scholar
  22. Huff R.M., Molinoff P.B., 1985, Assay of dopamine receptors with 3H-flupentixol, J. Pharm. Exp. Ther., 232:57–61.Google Scholar
  23. Hyttel J., 1978, Effects of neuroleptics on 3H-haloperidol binding and 3H-flupentixol binding and on adenylate cyclase in vitro, Life Sci., 23:551–556.PubMedCrossRefGoogle Scholar
  24. Hyttel J., 1981, Similarities between the binding of 3H-piflutixol and 3H-flupentixol to rat striatal dopamine receptors in vitro, Life Sci., 28:563–569.PubMedCrossRefGoogle Scholar
  25. Hyttel J., 1983, SCH 23390 — The first selective D1 antagonist, Eur. J. Pharmacol., 91:153–154.PubMedCrossRefGoogle Scholar
  26. Hyttel J., 1984, Dopamine D1 and D2 receptors. Characterization and differential effects of neuroleptics, VIIIth Int. Symposium on Med. Chem., (eds.) Dahlbom R. and Nilsson J.L.G., Swedish Pharmaceutical Press. Stockholm, pp 426–439.Google Scholar
  27. Hyttel J. and Arnt. J., Characterization of binding of 3H-SCH 23390 to D1 receptors. Correlation to other D1 and D2 measures and effects of selective lesions. J. Neurotransm., in press.Google Scholar
  28. Iorio L.C., Barnett A., Leitz F.H., Houser V.P. and Korduba C.A., 1983, SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems. J. Pharmacol. Exp. Ther., 226:462–468.PubMedGoogle Scholar
  29. Jenner P., Kilpatrick G.J. and Marsden C.D., 1984, CHAPS solubilizes D2 but not D1 binding sites from rat striatal preparations, Br. J. Pharmacol., 81:52P.Google Scholar
  30. Kebabian J.W. and Greengard P., 1972, Dopamine-sensitive adenyl cyclase: Possible Role in Synaptic Transmission, Science, 174:1346–1349.CrossRefGoogle Scholar
  31. Kebabian J.W., Chen T.C. and Cote T.E., 1979, Endogenous Guanyl nucleotides: components of the striatum which comfort Dopamine-sensitivity to adenylate cyclase, Comm. in Psychopharmacol., 3:421–428.Google Scholar
  32. Kebabian J. W. and Calne D.B., 1979, Multiple receptors for dopamine, Nature, 277:93–96.PubMedCrossRefGoogle Scholar
  33. Kohler C., Hall H., Oegren S.-O. and Gawell L., 1985, Specific in vitro and in vivo binding of 3H-Raclopride, Biochem. Pharmacol., 34:2251–2259.PubMedCrossRefGoogle Scholar
  34. Laduron P., Janssen P.F.M. and Leysen J.E., 1978, Spiperone: A ligand of choice for neuroleptic receptors, Biochem. Pharmacol, 27:317–321.PubMedCrossRefGoogle Scholar
  35. Leff S.E. and Creese I., 1985, Interactions of dopaminergic agonists and antagonists with dopaminergic D3 binding sites in rat striatum, Mol. Pharmacol., 27:184–192.PubMedGoogle Scholar
  36. Leff S.E., Hamblin M.W., and Creese I., 1985, Interactions of dopamine agonists with brain D1 receptors labelled by 3H-antagonists, Mol. Pharmacol., 27:171–183.PubMedGoogle Scholar
  37. Maguire M.E., 1984, Hormone sensitive magnesium transport and magnesium regulation of adenylate cyclase, TIPS, 5:73–77.Google Scholar
  38. Miller R.J., Horn A.S. and Iversen L.L., 1974, The action of neuroleptic drugs on dopamine-stimulated adenosine cyclic 3’,3’-monophosphate production in rat neostriatum and limbic forebrain, Mol. Pharmacol., 10:759–766.Google Scholar
  39. Molloy A.G. and Waddington J.L., 1984, Dopaminergic behaviour stereospecifically promoted by the D1 agonist R-SKF 38393 and selectively blocked by the D1 antagonist SCH 23390, Psychopharmacol., 82:409–410.CrossRefGoogle Scholar
  40. Morelli M. and Di Chiara G., 1985, Catalepsy induced by SCH 23390 in rats, Eur. J. Pharmacol., 37:717–723.Google Scholar
  41. Murrin L.C., 1983, Characteristics of 3H-flupentixol bindingin rat striatum, Life Sci., 33:2179–2186.PubMedCrossRefGoogle Scholar
  42. Nielsen M., Klimek V. and Hyttel J., 1984, Distinct target size of dopamine Da and D2 receptors in rat striatum, Life Sci., 35:325–332.PubMedCrossRefGoogle Scholar
  43. Ongini E., Caporali M.G. and Massotti M., 1985, Stimulation of dopamine D1 receptors by SKF 38393 induces EEG desynchronization and behavioral arousal, Life Sci., 37: 2377–2333.CrossRefGoogle Scholar
  44. Owen F., Poulter M., Mashal R.D., Crow T.J., Veall N. and Zanelli G.D., 1978, 77Br-p-Bromospiperone; a ligand for in vivo labelling of dopamine receptors, Life Sci., 33: 765–768.CrossRefGoogle Scholar
  45. Palmer G.C. and Manian A.A., 1976, Actions of Phenothiazine analogues on dopamine-sensitive adenylate cyclase in neuronal and glial-enriched fractions from rat brain, Biochem. Pharmacol., 25:63–71.PubMedCrossRefGoogle Scholar
  46. Pinoule C., Schoemaker H., Reynolds G.P., and Langer S.Z. 1985, 3H-SCH 23390 labeled D1 dopamine receptors are unchanged in schizophrenia and parkinson’s disease, Eur. J. Pharmacol., 114:235–237.CrossRefGoogle Scholar
  47. Proceddu M.L., Ongini E. and Biggio G., 1985, 3H-SCH 23390 binding sites increase after chronic blockade of D1 dopamine receptors, Eur. J. Pharmacol., 118:367–370.CrossRefGoogle Scholar
  48. Randrup A., Munkvad I., 1965, Special antagonism of amphetamine induced abnormal behaviour, Psychopharmacologia, 7:416–422.PubMedCrossRefGoogle Scholar
  49. Schulz D.W., Wyrick S.D., and Mailman R.B., 1984, 3H-SCH 23390 has the characteristics of a dopamine receptor ligand in the rat central nervous system, Eur. J. Pharmacol., 106:211–212.PubMedCrossRefGoogle Scholar
  50. Schulz D.W., Stanford E.J., Wyrick S.W., and Mailman R.B., 1985, Binding of 3H-SCH 23390 in rat brain: Regional distribution and effects of assay conditions and GTP suggest interactions at a D1-like dopamine D1 receptor, J. Neurochem., 45:1601–1611.PubMedCrossRefGoogle Scholar
  51. Seeman P., Chau-Wong M., Tedesco J. and Wong K., 1975, Brain receptors for antipsychotic drugs and dopamine: direct binding assays, Proc. Natl. Acad. Sci., USA, 72: 4376–4380.PubMedCrossRefGoogle Scholar
  52. Seeman P., Ulpian C., Grigoriadis D., Pri-Bar I. and Buchman O., 1985, Conversion of Dopamine D1 receptors from high to low affinity for dopamine, Biochem. Pharmacol., 34: 151–154.PubMedCrossRefGoogle Scholar
  53. Setler P.E., Sarau H.M., Zirkle C.L. and Saunders H.L., 1978, The central effects of a novel dopamine agonist, Eur. J. Pharmacol., 50:419–430.PubMedCrossRefGoogle Scholar
  54. Sidhu A. and Kebabian J.W, 1985, An Iodinated ligand identifying the D1 dopamine receptor, Eur. J. Pharmacol., 113:437–440.PubMedCrossRefGoogle Scholar
  55. White F.J. and Wang R.Y., Electrophysiological evidence for the existence of both D1 and D2 dopamine receptors in the rat nucleus accumbens, Mol. Neurosci., in press.Google Scholar

Copyright information

© Plenum Press, New York 1986

Authors and Affiliations

  • Peter H. Andersen
    • 1
  • Erik B. Nielsen
    • 1
  1. 1.Department of PharmacologyNOVO INDUSTRI A/SBagsvaerdDenmark

Personalised recommendations